Coronavirus Disease 2019-Associated Pulmonary Fibrosis: Clinical Findings, Pathogenesis, and Potential Treatment

0
0
0

Coronavirus Disease 2019-Associated Pulmonary Fibrosis: Clinical Findings, Pathogenesis, and Potential Treatment

As the COVID-19 pandemic enters its later stages, a growing concern has emerged: long-term lung damage in people who’ve recovered from the virus. For some, this damage takes the form of pulmonary fibrosis (PF)—scarring of lung tissue that can worsen over time, making it harder to breathe. A 2021 study by researchers from Tsinghua University and the China-Japan Friendship Hospital warns that PF could become one of the most severe complications of COVID-19, especially for older adults and those with severe initial infections.

What Is Post-COVID Pulmonary Fibrosis?

Pulmonary fibrosis is a progressive disease where scar tissue builds up in the lungs. Unlike temporary inflammation, this scarring is permanent—but early intervention can slow or stop its spread. For COVID-19 survivors, PF develops when the virus or the body’s immune response damages lung cells (called epithelial cells). These damaged cells trigger the growth of fibroblasts (cells that make scar tissue) and overproduction of extracellular matrix (a web of proteins that supports tissue). Over time, this leads to:

  • Thickened lung tissue
  • Reduced ability to take in oxygen
  • Symptoms like shortness of breath, fatigue, and coughing

Who’s at Risk?

Research from the original study and others highlights key risk factors for post-COVID PF:

  • Older age: Fibrosis patients were more likely to be older adults.
  • Severe initial infection: People who spent longer in the hospital, needed steroids or antivirals, or had high levels of inflammation markers (like C-reactive protein [CRP] and interleukin-6 [IL-6]) were at higher risk.
  • Mild infections too: Even people without obvious pneumonia symptoms can develop pulmonary fibrosis—biopsies of COVID-19 patients with cancer revealed lung damage without signs of pneumonia.

A stark example: An elderly woman with no prior lung disease died from severe bilateral PF after clearing the virus. Her autopsy revealed “honeycomb-like” lung remodeling—a late-stage fibrosis sign that underscores the condition’s lethality.

Imaging Clues to Early Fibrosis

Doctors use chest CT scans to spot early signs of PF. For COVID-19 patients who later developed fibrosis, initial scans often showed:

  • Irregular interfaces: Abnormal edges between lung tissue and airways.
  • Parenchymal bands: Thickened lines of scar tissue in the lung.
  • Other signs: Interstitial thickening (swollen lung walls), air bronchograms (visible airways in dense lung tissue), and coarse reticular patterns (net-like scars).

Nearly half of COVID-19 patients had fibrosis on CT scans, and the risk increased with how long they were sick. Even better: These scans correlate with clinical outcomes—higher fibrosis scores meant worse oxygen levels and harder breathing.

How COVID Triggers Lung Scarring

The path from COVID-19 to PF involves two key players: the virus itself and the immune system’s overreaction.

1. Viral Damage

SARS-CoV-2 (the virus that causes COVID-19) invades lung cells by attaching to the angiotensin-converting enzyme 2 (ACE2) receptor. This directly damages alveoli (the tiny air sacs where oxygen enters the blood), leading to diffuse alveolar damage (DAD)—a severe form of lung injury seen in autopsies of Chinese and Italian COVID-19 patients. DAD causes fluid buildup, blood clots, and damage to the cells that make surfactant (the substance that keeps alveoli open).

2. Immune System Overdrive

When the body can’t clear the virus quickly, the immune system goes into overdrive. Here’s how that leads to scarring:

  • T helper cell imbalance: Normally, Th1 cells (which fight viruses) and Th2 cells (which repair tissue) work in balance. But if the virus lingers, Th2 cells take over, triggering excess repair (scarring).
  • Macrophage dysfunction: Macrophages (immune cells that clean up debris) split into two types:
    • M1 macrophages: Release pro-inflammatory chemicals (like IL-6, IL-1β) to fight the virus.
    • M2 macrophages: Release anti-inflammatory chemicals (like TGF-β) to repair tissue—but too many M2 cells lead to excessive scarring.
  • Cytokine storm: A dangerous surge of inflammation where the body releases too many cytokines (immune signals). This increases blood vessel permeability (leaky capillaries), leading to fluid in the lungs, collapsed alveoli, and low oxygen levels. The resulting low-oxygen (hypoxic) environment further drives scarring.

Even mechanical ventilation—life-saving for severe COVID-19—can worsen fibrosis by triggering more inflammation and tissue repair.

Potential Treatments on the Horizon

No drugs are yet approved specifically for post-COVID PF, but researchers are testing promising options based on how the disease works:

1. Antivirals

Stopping the virus early can prevent long-term damage. While lopinavir-ritonavir (a HIV drug) didn’t help alone, a triple therapy (lopinavir-ritonavir + ribavirin + interferon β-1b) helped mild-to-moderate patients clear the virus faster. Other antivirals like favipiravir and chloroquine are still in trials.

2. Targeting Inflammation

  • Corticosteroids: Once controversial (they can slow virus clearance), steroids are now used to reduce severe inflammation in hospitalized patients.
  • IL-6 inhibitors: Tocilizumab (a drug for rheumatoid arthritis) targets IL-6—a key driver of cytokine storms and fibrosis. It’s being used off-label for COVID-19 patients with severe inflammation.
  • Anti-fibrotics: Pirfenidone (slows scarring) and nintedanib (blocks fibrosis-causing enzymes) are used for other fibrotic diseases. Researchers think they could help post-COVID PF, but clinical trials are needed.

3. Stem Cells

Mesenchymal stem cells (MSCs)—cells that can turn into lung cells—are being tested to repair damage. They reduce TGF-β (a scarring signal) and make surfactant. Early animal studies show promise, and human trials are underway.

4. Lung Transplant

For end-stage PF, transplant is the only cure—but it’s risky (rejection, cost) and not widely available.

The Road Ahead

Post-COVID PF is a growing public health threat, but much remains unknown. Will mild cases fully recover? Can early treatment stop fibrosis? How long does it take to progress? The original study’s authors stress that rigorous long-term studies are essential to answer these questions.

What’s clear: Awareness is key. If you’re a COVID-19 survivor with ongoing shortness of breath or fatigue, talk to your doctor about a lung function test or CT scan. Early detection could mean earlier intervention—and a better chance of slowing fibrosis.

References

  1. Das KM, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging 2017;27:342–349. doi:10.4103/ijri.IJRI_469_16
  2. Antonio GE, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology 2003;228:810–815. doi:10.1148/radiol.2283030726
  3. Kamal M, et al. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract 2020;e13746. doi:10.1111/ijcp.13746
  4. Yu M, et al. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol 2020;21:746–755. doi:10.3348/kjr.2020.0215
  5. Schwensen HF, et al. Fatal pulmonary fibrosis: a post-COVID-19 autopsy case. J Clin Pathol 2020;74:1–3. doi:10.1136/jclinpath-2020-206879
  6. Thille AW, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med 2013;1:395–401. doi:10.1016/S2213-2600(13)70053-5
  7. Shang Y, et al. Clinical characteristics and changes of chest CT features in 307 patients with common COVID-19 pneumonia infected SARS-CoV-2: a multicenter study in Jiangsu, China. Int J Infect Dis 2020;96:157–162. doi:10.1016/j.ijid.2020.05.006
  8. Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–232. doi:10.1016/S0140-6736(20)32656-8
  9. Qu JM, et al. Guidance for the management of adult patients with coronavirus disease 2019. Chin Med J 2020;133:1575–1594. doi:10.1097/CM9.0000000000000899
  10. Carsana L, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20:1135–1140. doi:10.1016/S1473-3099(20)30434-5
  11. Edler C, et al. Correction to: dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med 2020;134:1977. doi:10.1007/s00414-020-02336-7
  12. Pernazza A, et al. Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen. Virchows Arch 2020;477:743–748. doi:10.1007/s00428-020-02829-1
  13. Tian S, et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020;15:700–704. doi:10.1016/j.jtho.2020.02.010
  14. Cao B, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787–1799. doi:10.1056/NEJMoa2001282
  15. Hung IF, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:1695–1704. doi:10.1016/S0140-6736(20)31042-4
  16. Di Giambenedetto S, et al. Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol 2020;92:1787–1788. doi:10.1002/jmv.25897
  17. George PM, et al. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 2020;8:807–815. doi:10.1016/S2213-2600(20)30225-3
  18. Wu J, et al. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Res 2020;30:794–809. doi:10.1038/s41422-020-0354-1

Jiang YL, Dai HP, Wang C. Coronavirus disease 2019-associated pulmonary fibrosis: clinical findings, pathogenesis, and potential treatment. Chin Med J 2021;134:1792–1794. doi:10.1097/CM9.0000000000001464

Was this helpful?

0 / 0